PEPTAMEN® formulas are the only enteral nutrition formulas with 100% whey protein, available in a range of protein concentrations to facilitate:
*to standard polymeric tube feeding formulas†
† Enteral Nutrition Intolerance Brand Recommendation Claims Study conducted on behalf of Nestlé Health Science, May 2019
Tube feeding or enteral nutrition (EN) intolerance is reported to affect patient quality of life and to reduce EN volume delivered – which may result in nutrition deficits, dehydration and malnutrition.2
PEPTAMEN® is designed for tolerance and absorption:
CLICK HERE for PEPTAMEN® and Managing Intolerance Infographic
Enteral nutrition intolerance (ENI) or tube feeding intolerance has been reported as the most common complication associated with tube feeding. This Canadian study examines the prevalence and management of ENI in patients and individuals outside the ICU.
The benefits of early tube feeding in the ICU, barriers that may impede the delivery of early and adequate nutrition, and strategies to help minimize enteral feeding intolerance – presented from a nursing perspective.
Enteral nutrition (EN) intolerance, described as one or more gastrointestinal (GI) symptoms, is reported to affect patient quality of life and reduce EN volume delivered, which may result in nutrition deficits, dehydration and malnutrition. This study examines the prevalence and management of EN intolerance outside of the ICU setting.
Use the checklist to help determine if your patient may be experiencing tube feeding intolerance and to track severity and duration of symptoms. Refer to the Troubleshooting Guide for solutions to consider for managing intolerance symptoms.
Patient information about managing tube feeding at home. This guide is intended to support the tube feeding advice and instruction provided by healthcare professionals.
Information for the patient/family on why nutrition is important and specific considerations for individuals with gastrointestinal impairment. This booklet also contains information about how PEPTAMEN® is designed for gastrointestinal tolerance and absorption – in tube feeding or oral use.
Patients may present with a number of conditions, which may lead to higher protein needs. When a combination of these factors exists, it can have a profound influence on the protein needs of patients.
Adequate delivery of protein is important to optimize functional and clinical outcomes in patients with muscle loss related to age or muscle wasting associated with illness.14-17
PEPTAMEN® facilitates delivery of protein:
This presentation provides an overview of protein needs and protein metabolism in the context of the critically ill patient. Practical tips and considerations for clinical nutrition practice in the ICU are discussed, drawing on case examples and clinical experience.
Global experts in clinical nutrition and protein metabolism provide expert consensus opinion on provision of protein in the intensive care unit (ICU) and to help close the gap between what is happening in clinical practice and what is recommended by nutrition society guidelines.
A quality improvement study in Canadian ICUs showed PEPTAMEN® INTENSE 1.0 HP (enteral formula with 37% calories from protein) will deliver at least 80% prescribed protein needs in the ICU.
Whey protein has insulinotropic effects and has been shown to reduce postprandial glycemia in patients with acute and chronic hyperglycemia.19
Use of PEPTAMEN® INTENSE 1.0 HP as an enteral nutrition formula in the ICU can help:
Hyperglycemia is prevalent in the ICU and is associated with poor outcomes. The traditional treatment is insulin, but its use increases risk of hypoglycemia. New evidence suggests using a high protein, hypocaloric enteral formula with nutrients that have insulinotropic properties may help with blood glucose management and reduce frequency of insulin administered.
Hyperglycemia is prevalent in the ICU and is associated with poor outcomes. Use of a very high protein (37%), enzymatically hydrolyzed 100% whey protein, low CHO (29%) enteral nutrition formula was related to decreased hyperglycemic events and insulin administration in critically ill overweight/obese ICU patients.
For information on all Nestlé Health Science products: Nestlé Health Science Product Guide
1. Hopkins B et al. CJCN. 2017;5(2):82-101. 2. Bernard AC et al. NCP. 2004;19:481-486. 3. Fried MD et al. J Pediatr. 1992;120:569-72. 4. Khoshoo V et al. Eur J Clin Nutr. 2002;56:1-3. 5. Dangin M et al. J of Nutr. 2002;S3228-33. 6. Abrahao V. Curr Opin Clin Nutr Metab Care. 2012;15:480-484. 7. Grimble GK. Annu Rev Nutr. 1994;14:419-47. 8. Hannelore D. Annu Rev Physiol. 2004;66:361-84. 9. Maples B. JPEN. 2005;29:51. 10. Malone A et al. in Mueller C (Ed). 2012. Core Curr ASPEN. 11. Martindale R et al. in Gottschlich M (Ed). 2007. Core Curr ASPEN. 12. Hise M & Brown J. in Mueller C (Ed). 2012. Core Curr ASPEN. 13. Colaizzo-Anas T. in Mueller C (Ed). 2012. Core Curr ASPEN. 14. Little JP & Phillips SM. Appl Physiol Nutr Metab. 2009;34:817-828. 15. Moisey LL et al. Critical Care. 2013;17:R206. 16. Cruz-Jentoft AJ et al. Age and Ageing. 2010:1-12. 17. Fearon K et al. J Cachexia Sarcopenia Muscle. 2011;2:1-3. 18. Breen L & Phillips SM. Nutr & Metab. 2011;8(68):e-version. 19. Adams RL & Broughton KS. Ann Nutr Metab. 2016;69:56-63. 20. Ochoa JB et al. JPEN. 2017;41(2):289. 21. McClave SA et al. JPEN. 2015;39(2):240.